Company / Debt per Share
Taysha Gene Therapies, Inc. Debt per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Debt per Share
$0.24
FY2025
5-year range
$0.24 / $0.99
FY2021-FY2025
Trend
+4.0%
vs FY2024
Sector context
#73 of 82
Health Care
What the data says
Taysha Gene Therapies, Inc.'s debt per share of $0.24 is lower than 89% of companies in the Health Care sector (FY2025). Debt per Share returned to growth in FY2025 after 3 years of decline, reaching $0.24.
Based on SEC 10-K filings.
0.24 in FY2025 with a 3-year CAGR of -37.2%.
Improved from $0.64 to $0.24 over the past 2 years.
Health Care sector context is included.
Debt per Share over time
Growth rates
- 3-Year CAGR
- -37.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 82This company $0.24 Sector average $151.59
▼
-99.8% below sector average
Key checks
Key Insights
- In FY2025, debt per share increased 4.0% year-over-year.
- Ranks #73 out of 82 companies in the Health Care sector.
- Peak debt per share was recorded in FY2021.
- Lowest debt per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Debt per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.24 | +4.0% |
| FY2024 | $0.24 | -63.3% |
| FY2023 | $0.64 | -35.1% |
| FY2022 | $0.99 | -0.1% |
| FY2021 | $0.99 | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026